Regeneus Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

-3.53%

Revenues

Net income

-2m

L-61.51%

CFO

-660k

L-84.84%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Regeneus Ltd is an Australian clinical-stage company focused on regenerative medicine, creating cell-based treatments for various human health conditions. Its primary areas of research include osteoarthritis, a range of other musculoskeletal ailments, neuropathic pain, and dermatological disorders. The firm's leading platform technology, Progenza, offers a multi-synergistic therapy for addressing both osteoarthritis and neuropathic pain. Additionally, Regeneus is developing Sygenus, which targets the healing of skin wounds. Founded in 2007, the company's headquarters are located in Paddington, Australia.

URL

https://regeneus.com.au/

IPO date

Sep 19, 2013

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title AUD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title AUD in thousands, except ratios and share amounts	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06	2018‑06	2017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT